Jiayu Holding (300117.SZ) forecasted a net loss of 350 million to 500 million yuan for the year.
ST Jiayu (300117.SZ) discloses its performance forecast for the year 2024. The company expects a net profit attributable to shareholders of the listed company...
Jiayu Holding (300117.SZ) disclosed its performance forecast for the year 2024, with the company expecting a net loss attributable to shareholders of the listed company of 350 million to 500 million yuan; a net loss of 2.005 billion to 2.155 billion yuan after deducting non-recurring gains and losses.
The announcement shows that as of the end of the reporting period, the company's subsidiaries Guangdong Jiayu, Sichuan Jiayu, Jiangsu Jiayu and other subsidiaries have been appointed by the court's administrator and related affairs have been taken over by the administrator. The company will no longer include them in the scope of its consolidated financial statements. During the reporting period, due to the application of the creditors for judicial reorganization, the company focused its efforts on resolving the debt crisis, and the significant decrease in operating income year-on-year was mainly the result of the subsidiary's bankruptcy-related gains and losses, credit impairment and asset impairment provisions, deferred tax asset reversals, and provisions for new litigation-related operating expenses. There are no events that would require restating of financial data for the year 2024.
Related Articles

WEIMOB INC (02013) plans to discount approximately 8.87% of the total issued shares of 6.88 billion subscription shares, raising approximately 1.55 billion HKD.

ASCLETIS-B (01672) reported the latest breakthrough research on the novel fatty acid synthase (FASN) inhibitor Dehexastat (ASC40) for the treatment of acne in a dedicated session at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting.

DL Holdings GP (01709): Purchased 2.152 million shares under the restricted stock incentive plan for the year 2025.
WEIMOB INC (02013) plans to discount approximately 8.87% of the total issued shares of 6.88 billion subscription shares, raising approximately 1.55 billion HKD.

ASCLETIS-B (01672) reported the latest breakthrough research on the novel fatty acid synthase (FASN) inhibitor Dehexastat (ASC40) for the treatment of acne in a dedicated session at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting.

DL Holdings GP (01709): Purchased 2.152 million shares under the restricted stock incentive plan for the year 2025.
